Karam JA - Search Results

1

Blood biomarkers for prostate cancer detection and prognosis.

Shariat SF, Karam JA, Roehrborn CG. Shariat SF, et al. Among authors: karam ja. Future Oncol. 2007 Aug;3(4):449-61. doi: 10.2217/14796694.3.4.449. Future Oncol. 2007. PMID: 17661720 Review.

2

Molecular imaging in prostate cancer.

Karam JA, Mason RP, Koeneman KS, Antich PP, Benaim EA, Hsieh JT. Karam JA, et al. J Cell Biochem. 2003 Oct 15;90(3):473-83. doi: 10.1002/jcb.10636. J Cell Biochem. 2003. PMID: 14523981 Review.

3

Impact of training level of urology residents on the detection of prostate cancer on TRUS biopsy.

Karam JA, Shulman MJ, Benaim EA. Karam JA, et al. Prostate Cancer Prostatic Dis. 2004;7(1):38-40. doi: 10.1038/sj.pcan.4500695. Prostate Cancer Prostatic Dis. 2004. PMID: 14999236

4

Prostate-specific antigen doubling time predicts response to deferred antiandrogen therapy in men with androgen-independent prostate cancer.

Shulman MJ, Karam JA, Benaim EA. Shulman MJ, et al. Among authors: karam ja. Urology. 2004 Apr;63(4):732-6. doi: 10.1016/j.urology.2003.11.016. Urology. 2004. PMID: 15072890

5

The effect of combined androgen ablation on the expression of alpha1A-adrenergic receptor in the human prostate.

Benaim EA, Karam JA, Soboorian MH, Roehrborn CG, McConnell JD, Lin V. Benaim EA, et al. Among authors: karam ja. Prostate. 2004 Sep 1;60(4):310-6. doi: 10.1002/pros.20070. Prostate. 2004. PMID: 15264242 Clinical Trial.

6

Urinary levels of tumor-associated trypsin inhibitor (TATI) in the detection of transitional cell carcinoma of the urinary bladder.

Shariat SF, Herman MP, Casella R, Lotan Y, Karam JA, Stenman UH. Shariat SF, et al. Among authors: karam ja. Eur Urol. 2005 Sep;48(3):424-31. doi: 10.1016/j.eururo.2005.04.034. Eur Urol. 2005. PMID: 15963628

7

Pre-treatment nomogram for disease-specific survival of patients with chemotherapy-naive androgen independent prostate cancer.

Svatek R, Karakiewicz PI, Shulman M, Karam J, Perrotte P, Benaim E. Svatek R, et al. Eur Urol. 2006 Apr;49(4):666-74. doi: 10.1016/j.eururo.2005.11.032. Epub 2006 Jan 6. Eur Urol. 2006. PMID: 16423446

8

The application of epigenetic modifiers on the treatment of prostate and bladder cancer.

Zhang Z, Karam J, Frenkel E, Sagalowsky A, Hsieh JT. Zhang Z, et al. Urol Oncol. 2006 Mar-Apr;24(2):152-60. doi: 10.1016/j.urolonc.2005.11.004. Urol Oncol. 2006. PMID: 16520279 Review.

9

Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy.

Karam JA, Lotan Y, Karakiewicz PI, Ashfaq R, Sagalowsky AI, Roehrborn CG, Shariat SF. Karam JA, et al. Lancet Oncol. 2007 Feb;8(2):128-36. doi: 10.1016/S1470-2045(07)70002-5. Lancet Oncol. 2007. PMID: 17267327

10

Caveolin-1 overexpression is associated with aggressive prostate cancer recurrence.

Karam JA, Lotan Y, Roehrborn CG, Ashfaq R, Karakiewicz PI, Shariat SF. Karam JA, et al. Prostate. 2007 May 1;67(6):614-22. doi: 10.1002/pros.20557. Prostate. 2007. PMID: 17299799

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

295 results

Search Page

Filters